At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 33 target
Drug / intervention
FC084CSA+Tislelizumab combination (dose escalation) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors
In Brief
A Phase 2 clinical trial evaluating FC084CSA+Tislelizumab combination (dose escalation) and RP2D of FC084CSA+Tislelizumab combination (dose expansion) for Advanced Malignant Solid Tumors. Currently recruiting, targeting 33 participants across 1 site.
Detailed Summary
The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20252026
First PostedJul 2024
Enrollment StartNov 2024
Primary CompletionJul 2026
TodayJul 2026
Study CompletionOct 2026
First PostedJul 12, 2024
Enrollment StartNov 13, 2024
Primary CompletionJul 1, 2026
Study CompletionOct 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 2.0 years ago
Interventions
FC084CSA+Tislelizumab combination (dose escalation)drug
Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy
RP2D of FC084CSA+Tislelizumab combination (dose expansion)drug
RP2D of FC084CSA+fixed dose Tislelizumab combination therapy